サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Multiple Myeloma Treatment Market Research Report - Global Forecast till 2023

多発性骨髄腫治療市場調査レポート-2023年までの世界予測

レポート概要

世界の多発性骨髄腫治療市場調査レポート:治療法別(化学療法、放射線療法、幹細胞移植、コルチコステロイド、インターフェロン、その他)、エンドユーザー別(病院、クリニック、独立系薬局、その他)‐2023年までの予測

市場シナリオ

世界の多発性骨髄腫治療市場は予測期間中(2018−2023)に11.0%のCAGRで堅調に拡大することが予想されます。多発性骨髄腫は形質細胞のがんです。血漿は骨髄の中にあり、免疫系の重要な部分です。免疫系は、共に感染症やその他の疾患と闘うためのT細胞、B細胞など、複数の細胞で構成されています。リンパ球は免疫系における白血球の重要な種類の一つです。体内の多くの部分にリンパ節、骨髄、腸、血流といった種類の異なるリンパ球が存在しています。世界の多発性骨髄腫市場の成長要因としては、人口の高齢化、医療費の増加、新規がん治療薬の使用の増加が挙げられます。

そのほか、開発中の薬剤も有望視されており、今後は生物学的製剤や幹細胞療法も市場をけん引するでしょう。その一方で、高い治療費や限定的な患者数などが成長の妨げとなります。

レポート詳細

目次

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Multiple Myeloma Treatment Market, by Treatment
6.1 Introduction
6.2 Chemotherapy
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.2.1 Bendamustine (Treanda)
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.2.2 Cyclophosphamide (Cytoxan)
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.2.3 Doxorubicin (Adriamycin)
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.2.4 Etoposide
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.2.5 Liposomal doxorubicin (Doxil)
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.2.6 Melphalan (Alkeran, Evomela)
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.2.7 Vincristine (Oncovin)
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.3 Corticosteroids
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.4 Interferon
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.5 Stem Cell Transplant
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.6 Radiation therapy
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023

Chapter 7. Global Multiple Myeloma Treatment Market, by End-User
7.1 Introduction
7.2 Hospitals
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.3 Clinics
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.4 Independent Pharmacies
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.5 Other
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023

Chapter 8. Global Multiple Myeloma Treatment Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 UK
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia-Pacific
8.5 Middle East & Africa
8.5.1 Middle East
8.5.2 Africa

Chapter 9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies

Chapter 10. Company Profiles
10.1 Celgene Corporation
10.1.1 Company Overview
10.1.2 Product Overview
10.1.3 Financials Overview
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Janssen Biotech, Inc.
10.2.1 Company Overview
10.2.2 Product Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Bristol-Myers Squibb Company
10.3.1 Company Overview
10.3.2 Product Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Product Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Millennium Pharmaceuticals
10.5.1 Company Overview
10.5.2 Product Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Amgen, Inc
10.6.1 Company Overview
10.6.2 Product Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Genzyme Corporation
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financial Overview
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Juno Therapeutics
10.8.1 Overview
10.8.2 Product Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.7 Johnson & Johnson
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 F. Hoffmann-La Roche Ltd
10.8.1 Overview
10.8.2 Product Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.11 GlaxoSmithKline plc
10.91 Overview
10.92 Product Overview
10.93 Financials
10.94 Key Developments
10.95 SWOT Analysis
10.10 AbbVie Inc
10.10.1 Overview
10.10.2 Product Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.13 Innate Pharma SA
10.13.1 Overview
10.13.2 Product Overview
10.13.3 Financials
10.13.4 Key Developments
10.13.5 SWOT Analysis
10.14 Celldex Therapeutics, Inc
10.14.1 Overview
10.14.2 Product Overview
10.14.3 Financials
10.14.4 Key Developments
10.14.5 SWOT Analysis
10.15 Onyx Pharmaceuticals
10.15.1 Overview
10.15.2 Product Overview
10.15.3 Financials
10.15.4 Key Developments
10.15.5 SWOT Analysis
10.16 Pfizer
10.16.1 Overview
10.16.2 Product Overview
10.16.3 Financials
10.16.4 Key Developments
10.16.5 SWOT Analysis
10.17 Takeda Pharmaceuticals
10.17.1 Overview
10.17.2 Product Overview
10.17.3 Financials
10.17.4 Key Developments
10.17.5 SWOT Analysis

Chapter 11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s Viewpoint
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Predictions for the Multiple Myeloma Treatment Market

Chapter 12. Appendix

LIST OF TABLES
Table 1 Global Multiple Myeloma Treatment Market Synopsis, 2018-2023
Table 2 Global Multiple Myeloma Treatment Market Estimates and Forecast, 2018-2023 (USD Million)
Table 3 Global Multiple Myeloma Treatment Market, by Region, 2018-2023 (USD Million)
Table 4 Global Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 5 Global Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)
Table 6 North America: Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 7 North America: Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)
Table 8 US: Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 9 US: Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)
Table 10 Canada: Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 11 Canada: Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)
Table 12 South America: Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 13 South America: Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)
Table 14 Europe: Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 15 Europe: Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)
Table 16 Western Europe: Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 17 Western Europe: Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)
Table 18 Eastern Europe: Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 19 Eastern Europe: Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)
Table 20 Asia-Pacific: Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 21 Asia-Pacific: Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)
Table 22 Middle East & Africa: Multiple Myeloma Treatment Market, by Treatment, 2018-2023 (USD Million)
Table 23 Middle East & Africa: Multiple Myeloma Treatment Market, by End-User, 2018-2023 (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Multiple Myeloma Treatment Market
Figure 3 Segmentation Market Dynamics for Global Multiple Myeloma Treatment Market
Figure 4 Global Multiple Myeloma Treatment Market Share, by Treatment, 2017
Figure 5 Global Multiple Myeloma Treatment Market Share, by End-User, 2017
Figure 6 Global Multiple Myeloma Treatment Market Share, by Region, 2017
Figure 7 North America: Multiple Myeloma Treatment Market Share, by Country, 2017
Figure 8 Europe: Multiple Myeloma Treatment Market Share, by Country, 2017
Figure 9 Asia-Pacific: Multiple Myeloma Treatment Market Share, by Country, 2017
Figure 10 Middle East & Africa: Multiple Myeloma Treatment Market Share, by Country, 2017
Figure 11 Global Multiple Myeloma Treatment Market: Company Share Analysis, 2017 (%)
Figure 12 Celgene Corporation: Key Financials
Figure 13 Celgene Corporation: Segmental Revenue
Figure 14 Celgene Corporation: Geographical Revenue
Figure 15 Janssen Biotech, Inc.: Key Financials
Figure 16 Janssen Biotech, Inc.: Segmental Revenue
Figure 17 Janssen Biotech, Inc.: Geographical Revenue
Figure 18 Bristol-Myers Squibb Company: Key Financials
Figure 19 Bristol-Myers Squibb Company: Segmental Revenue
Figure 20 Bristol-Myers Squibb Company: Geographical Revenue
Figure 21 Novartis AG: Key Financials
Figure 22 Novartis AG: Segmental Revenue
Figure 23 Novartis AG: Geographical Revenue
Figure 24 Millennium Pharmaceuticals: Key Financials
Figure 25 Millennium Pharmaceuticals: Segmental Revenue
Figure 26 Millennium Pharmaceuticals. Geographical Revenue
Figure 27 Amgen, Inc: Key Financials
Figure 28 Amgen, Inc: Segmental Revenue
Figure 29 Amgen, Inc: Geographical Revenue
Figure 30 Genzyme Corporation: Key Financials
Figure 31 Genzyme Corporation: Segmental Revenue
Figure 32 Genzyme Corporation: Geographical Revenue
Figure 33 Juno Therapeutics: Key Financials
Figure 34 Juno Therapeutics: Segmental Revenue
Figure 35 Juno Therapeutics: Geographical Revenue
Figure 36 Johnson & Johnson: Key Financials
Figure 37 Johnson & Johnson: Segmental Revenue
Figure 38 Johnson & Johnson: Geographical Revenue
Figure 39 F. Hoffmann-La Roche Ltd: Key Financials
Figure 40 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 41 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 42 GlaxoSmithKline plc: Key Financials
Figure 43 GlaxoSmithKline plc: Segmental Revenue
Figure 44 GlaxoSmithKline plc: Geographical Revenue
Figure 45 AbbVie Inc: Key Financials
Figure 46 AbbVie Inc: Segmental Revenue
Figure 47 AbbVie Inc: Geographical Revenue
Figure 48 Innate Pharma SA: Key Financials
Figure 49 Innate Pharma SA: Segmental Revenue
Figure 50 Innate Pharma SA: Geographical Revenue
Figure 51 Celldex Therapeutics, Inc: Key Financials
Figure 52 Celldex Therapeutics, Inc: Segmental Revenue
Figure 53 Celldex Therapeutics, Inc: Geographical Revenue
Figure 54 BrainScope Company, Inc, Inc: Key Financials
Figure 55 BrainScope Company, Inc, Inc: Segmental Revenue
Figure 56 BrainScope Company, Inc, Inc: Geographical Revenue
Figure 57 Pfizer, Inc: Key Financials
Figure 58 Pfizer, Inc: Segmental Revenue
Figure 59 Pfizer, Inc: Geographical Revenue
Figure 60 Takeda Pharmaceuticals, Inc: Key Financials
Figure 61 Takeda Pharmaceuticals, Inc: Segmental Revenue
Figure 62 Takeda Pharmaceuticals, Inc: Geographical Revenue
Figure 63 Onyx Pharmaceuticals: Key Financials
Figure 64 Onyx Pharmaceuticals: Segmental Revenue
Figure 65 Onyx Pharmaceuticals: Geographical Revenue
Figure 66 Silver Creek Pharmaceuticals Inc: Key Financials
Figure 67 Silver Creek Pharmaceuticals Inc: Segmental Revenue
Figure 68 Silver Creek Pharmaceuticals Inc: Geographical Revenue
Figure 69 Stemedica Cell Technologies Inc: Key Financials
Figure 70 Stemedica Cell Technologies Inc: Segmental Revenue
Figure 71 Stemedica Cell Technologies Inc: Geographical Revenue
Figure 72 Banayan Biomarkers Inc: Key Financials
Figure 73 Banayan Biomarkers Inc: Segmental Revenue
Figure 74 Banayan Biomarkers Inc: Geographical Revenue
Figure 75 Vasopharm GmbH: Key Financials
Figure 76 Vasopharm GmbH: Segmental Revenue
Figure 77 Vasopharm GmbH: Geographical Revenue

発刊日

2018/12

体裁

PDF / 85ページ

販売価格

4,450USD

発行

Market Research Future

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

医薬品原料・製剤 / 疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE